DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tamiflu (Oseltamivir Phosphate) - Published Studies

 
 



Tamiflu Related Published Studies

Well-designed clinical trials related to Tamiflu (Oseltamivir)

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. [2014]

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. [2013]

Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). [2011.09]

Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. [2011.09]

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. [2011.08.16]

Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. [2010.12]

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. [2010.11.15]

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. [2010.11.02]

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. [2010.10.15]

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. [2010.06]

Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. [2010.06]

Safety and pharmacokinetics of oseltamivir at standard and high dosages. [2010.05]

Use of oseltamivir in the treatment of canine parvoviral enteritis. [2010.02]

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. [2010]

Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers. [2009.08]

Pharmacokinetics and tolerability of oseltamivir combined with probenecid. [2008.09]

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. [2008.01]

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. [2006.11.10]

Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus. [2006.09]

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. [2006.01]

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. [2005.03]

[A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients] [2004.12.17]

[A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population] [2004.07]

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. [2004.02.01]

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. [2003.07.28]

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. [2003.05.12]

A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. [2003.01]

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. [2002.10]

Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection. [2002.02]

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. [2002.01]

[A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza] [2001.12]

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. [2001.08]

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. [2001.02.15]

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. [2001.02.14]

Oral oseltamivir treatment of influenza in children. [2001.02]

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. [2001]

[Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial] [2000.12]

Oral oseltamivir in human experimental influenza B infection. [2000.09]

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. [2000.08]

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. [2000.05.27]

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. [2000.02.23]

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. [1999.10.28]

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. [1999.10.06]

Well-designed clinical trials possibly related to Tamiflu (Oseltamivir)

Efficacy and safety of EchinaforceĀ® in respiratory tract infections. [2013]

Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). [2012]

Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. [2011.09]

Neuraminidase inhibitors for influenza treatment and prevention in healthy adults. [2010.08.01]

Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. [2009.10.06]

Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. [2007.02]

Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. [2005.10]

Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. [2005]

Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. [2001.07]

Other research related to Tamiflu (Oseltamivir)

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. [2014]

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. [2014]

A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. [2013]

Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. [2013]

Effectiveness of a new bioequivalent formulation of oseltamivir (EnfluvirĀ®) on 2010-2011 seasonal influenza viruses: an open phase IV study. [2012]

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial. [2012]

Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study. [2012]

Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. [2012]

Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. [2011.12]

Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory. [2011.12]

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial. [2011.11.26]

Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. [2011.11]

Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season. [2011.11]

Pharmacokinetics and Safety of Coadministered Oseltamivir and Rimantadine in Healthy Volunteers: An Open-Label, Multiple-Dose, Randomized, Crossover Study. [2011.10.30]

Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin. [2011.10.05]

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan. [2011.10]

Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans. [2011.09.29]

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. [2011.09]

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. [2011.08.01]

Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. [2011.08]

Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus. [2011.08]

Compliance to oseltamivir and subsequent occurrence of self-reported adverse drug reactions among nursery and primary school children following exposure to Influenza A(H1N1)v. [2011.05]

Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy. [2011.05]

Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction. [2011.01]

Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. [2011]

Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. [2011]

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. [2011]

Oseltamivir dosing for influenza infection in premature neonates. [2010.08.15]

[Naturally occurring oseltamivir resistance in influenza A] [2010.08.09]

Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. [2010.07.20]

First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. [2010.07]

Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. [2010.07]

Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. [2010.06.10]

Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009. [2010.06.10]

Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. [2010.06.01]

Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. [2010.05.13]

Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. [2010.05]

[Oseltamivir in pregnancy, lactation and neonatal period--comparison of international recommendations] [2010.04]

[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient] [2010]

Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. [2010]

Use of oseltamivir in the treatment of canine parvoviral enteritis. [2010]

Safety and pharmacokinetics of oseltamivir at standard and high dosages. [2010]

Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. [2009.11]

Surveillance and oseltamivir resistance of human influenza a virus in Turkey during the 2007-2008 season. [2009.09]

Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. [2009.08.28]

Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. [2009.08]

Oseltamivir (tamiflu) is a substrate of peptide transporter 1. [2009.08]

Extending the environmental risk assessment for oseltamivir (Tamiflu) under pandemic use conditions to the coastal marine compartment. [2009.08]

Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. [2009.07.30]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014